Clinical Outcomes after Oat Beta-Glucans Dietary Treatment in Gastritis Patients.

Sylwia Gudej,Joanna Gromadzka-Ostrowska,Michał Oczkowski,Małgorzata Juszczak,Joanna Harasym,Katarzyna Dziendzikowska,Małgorzata Jałosińska,Ewa Lange,Jacek Wilczak,Rafał Filip

doi:10.3390/nu13082791

Abstract

The prevalence of gastritis in humans is constantly growing and a prediction of an increase in this health problem is observed in many countries. For this reason, effective dietary therapies are sought that can alleviate the course of this disease. The objective of this study was to determine the effect of chemically pure oat beta-glucan preparations with different molar masses, low or high, used for 30 days in patients with histologically diagnosed chronic gastritis. The study enrolled 48 people of both genders of different ages recruited from 129 patients with a gastritis diagnosis. Before and after the therapy, hematological, biochemical, immunological and redox balance parameters were determined in the blood and the number of lactic acid bacteria and SCFA concentrations in the feces. Our results demonstrated a beneficial effect of oat beta-glucans with high molar mass in chronic gastritis in humans, resulting in reduced mucosal damage and healthy changes in SCFA fecal concentration and peripheral blood serum glutathione metabolism and antioxidant defense parameters. This fraction of a highly purified oat beta-glucan is safe for humans. Its action is effective after 30 days of use, which sheds new light on the nutritional treatment of chronic gastritis.

Highlights

Gastritis is usually diagnosed by the histological characteristics of tissue samples after a gastric mucosal biopsy, especially during routine upper esophagogastroduodenoscopy [1].Helicobacter pylori infection is considered the main factor responsible for developing the inflammatory changes in gastric mucosa
The included patients consisted of women and men aged 23–74 with BMI 17.0–38.8 kg/m2, who were randomly assigned to three following dietary groups, with 16 patients each: placebo group (P), oat beta-glucan with a high molar mass group (G1) and oat beta-glucan with low molar mass (G2)
Compliance with the treatment regimen was calculated from the number of study products dispensed to the subjects, and the number of study products returned to the study site

Summary

Introduction

Helicobacter pylori infection is considered the main factor responsible for developing the inflammatory changes in gastric mucosa. Gastritis risk factors comprise inappropriate diet, non-steroid anti-inflammatory drugs (NSAIDs) and other drugs, excessive alcohol use, smoking, stress and older age [3]. There are no specific recommendations for treating chronic gastritis in the case of. Natural supplements or herbal medicines are recommended to patients. It is still controversial for many clinicians if, for non-ulcer patients with H. pylori infection, eradication therapy should be advised [4]. Many drugs are used to prevent and treat H. pylorinegative gastritis, only PPIs have proven their efficacy, especially in high-risk patients [5]

Objectives

Methods

Results

Discussion

Conclusion